PAVmed Inc. (NASDAQ:PAVM) Sees Significant Decrease in Short Interest

PAVmed Inc. (NASDAQ:PAVM) saw a significant drop in short interest in May. As of May 29th, there was short interest totaling 8,301 shares, a drop of 36.3% from the May 14th total of 13,031 shares. Based on an average daily trading volume, of 7,904 shares, the short-interest ratio is presently 1.1 days. Currently, 1.0% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on PAVM. Weiss Ratings restated a “sell (d)” rating on shares of PAVmed in a report on Tuesday, April 21st. Ascendiant Capital Markets dropped their price target on shares of PAVmed from $65.00 to $56.00 and set a “buy” rating on the stock in a research report on Monday, June 8th. Finally, Wall Street Zen raised shares of PAVmed from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $56.00.

PAVmed Price Performance

Shares of PAVM traded down $0.09 on Wednesday, hitting $4.90. The company’s stock had a trading volume of 12,276 shares, compared to its average volume of 12,959. The company has a market capitalization of $4.88 million, a PE ratio of -0.13 and a beta of 0.58. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.02 and a quick ratio of 2.02. PAVmed has a fifty-two week low of $4.50 and a fifty-two week high of $28.44. The company has a 50 day moving average price of $7.27 and a 200 day moving average price of $8.70.

PAVmed (NASDAQ:PAVM) last announced its earnings results on Friday, May 15th. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.48). The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.07 million. PAVmed had a negative return on equity of 146.19% and a negative net margin of 21,914.12%. On average, research analysts anticipate that PAVmed will post -2.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On PAVmed

An institutional investor recently raised its position in PAVmed stock. Jane Street Group LLC boosted its stake in shares of PAVmed Inc. (NASDAQ:PAVM) by 392.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 52,676 shares of the company’s stock after acquiring an additional 41,990 shares during the quarter. Jane Street Group LLC owned approximately 0.31% of PAVmed worth $32,000 as of its most recent SEC filing. 19.93% of the stock is owned by institutional investors and hedge funds.

PAVmed Company Profile

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.